Ignite Creation Date:
2024-05-05 @ 4:51 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00329927
Status:
COMPLETED
Last Update Posted:
2006-09-14
First Post:
2006-05-23
Brief Title:
Safety and Immunogenicity of a Commercially Available Influenza Vaccine Formulation 20062007 When Administered to Elderly Subjects
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A Phase II Open Label Uncontrolled Multi Center Study to Evaluate Safety and Immunogenicity of a Commercially Available Surface Antigen Inactivated Adjuvanted With MF59C1 Influenza Vaccine Formulation 2006-2007 When Administered to Elderly Subjects
Status:
COMPLETED
Status Verified Date:
2006-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
To evaluate the antibody response to each influenza vaccine antigen when administering a single dose to subjects aged 65 years and over
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| Eudract number | None | None | None |
| 2006-000610-20 | None | None | None |